Mangoceuticals (NASDAQ: MGRX) closes 74% premium stock sale with warrants

What happened

Mangoceuticals, Inc. (NASDAQ: MGRX) closed a registered direct offering on October 9, 2026 for about $492,750. The company sold 657,000 shares of common stock together with 657,000 warrants at $0.75 per unit, and the unit price was about 74% above the referenced $0.43 close. Each warrant can buy one share at $1.00, becomes exercisable immediately and expires five years after issuance.

The warrants also limit exercise if a holder would exceed 4.99% or, at the holder's election, 9.99% of outstanding common stock.

The company said the shares and warrants were sold together, but issued separately, and the proceeds are for working capital and general corporate purposes. Mangoceuticals also said it develops, markets and sells health and wellness products through telemedicine platforms under the MangoRx and PeachesRx brands.

Separately, MangoRx IP Holdings, LLC entered agreements for $2.5 million in aggregate strategic investment commitments in exchange for a 25% membership interest. MangoRx IP had received $1.75 million of that capital, with $750,000 due by November 28, 2026. The subsidiary financing is intended to support commercialization of MangoRx IP's intellectual property portfolio without issuing parent-company securities.

Key numbers

Metric	Latest	Change	Source
Gross proceeds from the offering	$492,750		SEC 8-K
Shares of common stock sold	657,000 shares		SEC 8-K
Warrants issued	657,000 warrants		SEC 8-K
Unit price	$0.75 per unit		SEC 8-K
Premium to recent closing share price	74%		Press release
Strategic investment commitments at MangoRx IP Holdings	$2.5 million		Press release
Remaining commitment due by November 28, 2026	$750,000		Press release

Read more: Mangoceuticals (MGRX) stock analysis and investment case

Why it matters

OptimistFi's case is that Mangoceuticals has to keep funding growth without letting dilution outrun progress, and this filing shows both sides of that tradeoff. MangoRx IP Holdings had already received 70% of the committed capital, so the subsidiary piece is partly funded.

The parent raise still adds stock and warrants, while the subsidiary deal uses a separate structure that does not issue parent-company securities. That gives investors a clearer look at how management is balancing cash needs across the business.

The filing also says investors should review the Form 8-K for dilution that could result from warrant exercises, and the offering can create up to 788,400 Warrant Shares. That leaves a longer dilution tail even after the cash arrives.

Browse: stock research on every company OptimistFi covers

What's next

The next dated milestone is November 28, 2026, when the remaining $750,000 of MangoRx IP commitments is due. If that tranche arrives, the subsidiary capital raise will be completed as described. If it does not, the capital plan will remain only partly funded.

More from OptimistFi